2. Search Result
Search Result
Results for "

P2Y14

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Biochemical Assay Reagents

13

Natural
Products

4

Isotope-Labeled Compounds

2

Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N7032
    Uridine 5′-diphosphoglucose disodium
    Maximum Cited Publications
    8 Publications Verification

    UDP-D-Glucose disodium

    		 Endogenous Metabolite P2Y Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
    Uridine 5′-diphosphoglucose disodium
  • HY-114364
    UDP-Galactose disodium
    4 Publications Verification

    		 Endogenous Metabolite P2Y Receptor Metabolic Disease
    UDP-Galactose disodium is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose disodium is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose disodium can be used to study cell signal transduction and substance metabolism .
    UDP-Galactose disodium
  • HY-W010832
    Uridine-5'-diphosphate disodium salt
    2 Publications Verification

    		 P2Y Receptor DNA/RNA Synthesis Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    Uridine-5'-diphosphate disodium salt is a potent, selective P2Y6 receptor native agonist (EC50=300 nM; pEC50=6.52 for human P2Y6 receptor). Uridine-5'-diphosphate disodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis .
    Uridine-5'-diphosphate disodium salt
  • HY-110322A
    PPTN
    4 Publications Verification

    		 P2Y Receptor Inflammation/Immunology
    PPTN, a chemical probe, is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .
    PPTN
  • HY-110322
    PPTN hydrochloride
    4 Publications Verification

    		 P2Y Receptor Inflammation/Immunology
    PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity .
    PPTN hydrochloride
  • HY-W010820
    Uridine 5'-diphosphate sodium salt
    2 Publications Verification

    		 P2Y Receptor DNA/RNA Synthesis Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    Uridine 5'-diphosphate sodium salt is a potent, selective P2Y6 receptor native agonist (EC50=300 nM; pEC50=6.52) and a potent P2Y14 antagonist (pEC50=7.28). Uridine 5'-diphosphate sodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis .
    Uridine 5'-diphosphate sodium salt
  • HY-N7114A
    Chloramphenicol succinate sodium
    3 Publications Verification

    		 Bacterial P2Y Receptor Succinate Dehydrogenase Drug Intermediate Infection Inflammation/Immunology
    Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
    Chloramphenicol succinate sodium
  • HY-113044R
    Uridine 5′-diphosphoglucose (Standard)

    UDP-D-Glucose (Standard)

    		 Reference Standards Endogenous Metabolite P2Y Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Uridine 5′-diphosphoglucose (Standard) (UDP-D-Glucose (Standard)) is the analytical standard of Uridine 5′-diphosphoglucose (HY-113044). This product is intended for research and analytical applications. Uridine 5’-diphosphoglucose (UDP-glucose), secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
    Uridine 5′-diphosphoglucose (Standard)
  • HY-150524
    UDP-Galactose

    		Endogenous Metabolite P2Y Receptor Metabolic Disease
    UDP-Galactose is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose can be used to study cell signal transduction and substance metabolism .
    UDP-Galactose
  • HY-N8599
    Cichoriin
    2 Publications Verification

    		 Amylases Glycosidase Lipase Dipeptidyl Peptidase p38 MAPK PPAR P2Y Receptor NOD-like Receptor (NLR) SARS-CoV Pyroptosis GLUT Angiotensin-converting Enzyme (ACE) NF-κB Infection Metabolic Disease Inflammation/Immunology
    Cichoriin is an orally active coumarin glycoside with broad biological activities. Cichoriin exhibits inhibitory activities against α-amylase, α-glucosidase, pancreatic lipase and DPP-IV, with IC50 values of 5.76, 2.94, 16.83 and 9.16 μg/mL, respectively. Cichoriin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) in mice by activating the AMPK signaling pathway. Cichoriin upregulates PPAR-γ in adipose tissue and alleviates obesity and associated cardiorenal injury in rats. Cichoriin blocks monosodium urate crystal-induced activation of the NLRP3 inflammasome and cell pyroptosis by inhibiting P2Y14R (IC50 = 8.47 nM). In silico virtual screening reveals that Cichoriin has a strong binding affinity for SARS-CoV-2 .
    Cichoriin
  • HY-113044
    Uridine 5′-diphosphoglucose

    UDP-D-Glucose

    		 Endogenous Metabolite P2Y Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Uridine 5’-diphosphoglucose (UDP-glucose), secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue .
    Uridine 5′-diphosphoglucose
  • HY-162661
    P2Y14R antagonist 2

    		P2Y Receptor Inflammation/Immunology
    P2Y14R antagonist 2 (compound 39) is a potent, selective and orally active P2Y14R antagonist with an IC50 value of 0.40 nM. P2Y14R antagonist 2 shows anti-inflammatory activity. P2Y14R antagonist 2 has the potential for the research of colitis .
    P2Y14R antagonist 2
  • HY-161727
    P2Y14R antagonist 1

    		P2Y Receptor NOD-like Receptor (NLR) Inflammation/Immunology
    P2Y14R antagonist 1 (compound I-17) is a selective P2Y14R antagonist with an IC50 of 0.6 nM. It exhibits potent P2Y14R antagonistic activity, both in vitro and in vivo efficacy, and favorable pharmacokinetic profiles. P2Y14R antagonist 1 reduces the release of inflammatory factors and cell pyroptosis through the NOD-like receptor family pyrin domain-containing 3 (NLRP3)/gasdermin D (GSDMD) signaling pathway. P2Y14R antagonist 1 holds promise for research in the field of acute gouty arthritis .
    P2Y14R antagonist 1
  • HY-148596
    UDP-GlcNAc

    UDP-N-Acetyl-D-glucosamine; Uridine diphospho-N-acetylglucosamine; UDP-N-acetylglucosamine

    		 Endogenous Metabolite P2Y Receptor Drug Intermediate Glycosyltransferase Infection
    UDP-GlcNAc (UDP-N-Acetyl-D-glucosamine) is an important component and precursor of bacterial peptidoglycan. UDP-GlcNAc is a nucleotide sugar used by Glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is the sugar nucleotide donor for the synthesis of O-GlcNAc modified proteins. UDP-GlcNAc also acts as a full agonist of the P2Y14 receptor and inhibits the formation of cAMP. UDP-GlcNAc can be used in studies related to bacterial infections .
    UDP-GlcNAc
  • HY-170950
    P2Y14 antagonist 1

    		P2Y Receptor NOD-like Receptor (NLR) Inflammation/Immunology
    P2Y14 antagonist 1 (compound 45) is a high selective and orally active P2Y14R antagonist with an IC50 of 0.70 nM. P2Y14R antagonist 1 demonstrates significant anti-inflammatory efficacy, effectively mitigating the pulmonary infiltration of immune cells and inflammatory response through suppressing the NLRP3 signaling pathway. P2Y14R antagonist 1 has the potential for the research of acute lung injury .
    P2Y14 antagonist 1
  • HY-161343
    HDL-16

    		P2Y Receptor Necroptosis Inflammation/Immunology
    HDL-16 is a potent P2Y14R antagonist with an IC50 of 0.3095 nM. HDL-16 ameliorates DSS (HY-116282C)-induced colitis through suppressing necroptosis of intestinal epithelium cells (IECs) and protecting mucosal barrier function .
    HDL-16
  • HY-179133
    HDB-1

    		P2Y Receptor PKA Raf MEK ERK Inflammation/Immunology
    HDB-1 is a selective inhibitor of the P2Y14 receptor (P2Y14R) with an IC50 of 26 pM. HDB-1 shows no significant inhibition on P2Y1R, P2Y2R, P2Y4R, P2Y6R, and P2Y12R. HDB-1 blocks the activation of hepatic stellate cells (HSC) by inhibiting the PKA/Raf1/MEK/ERK signaling pathway mediated by P2Y14R, thereby alleviating the core pathological process of liver fibrosis. HDB-1 can be used for the study of liver fibrosis .
    HDB-1
  • HY-178006
    MRS4917

    		P2Y Receptor Neurological Disease
    MRS4917 is an orally active, potent selective P2Y14 receptor (hP2Y14R) antagonist (IC50 = 2.88 nM, Ki = 1.67 nM) that shows >18,000 fold selectivity against P2Y6R (IC50 = 54 μM). MRS4917 demonstrates oral efficacy in reversing established mechanoallodynia in the chronic constriction injury (CCI) mouse model, while having no effect on thermoregulation. MRS4917 can be used for neurological diseases research .
    MRS4917
  • HY-114364S
    UDP-α-D-Galactose-13C disodium

    		Isotope-Labeled Compounds Others
    UDP-α-D-Galactose- 13C disodium is the 13C labeled UDP-α-D-Galactose disodium. UDP-Galactose disodium is a monosaccharide and a key glycosyl donor molecule in cells that participates in nucleotide sugar metabolism. UDP-Galactose disodium is the natural agonist of the P2Y14 receptor coupled to Gi proteins in the immune system (IC50 = 0.67 μM, hP2Y14). UDP-Galactose disodium can be used to study cell signal transduction and substance metabolism .
    UDP-α-D-Galactose-13C disodium
  • HY-131822
    5'-UMPS

    Uridine-5'-O-monophosphorothioate

    		 P2Y Receptor Cancer
    5'-UMPS (Uridine-5'-O-monophosphorothioate) is a P2Y14 receptor agonist. 5'-UMPS can induce HeLa cell growth slightly .
    5'-UMPS
  • HY-N7032S1
    Uridine 5′-diphosphoglucose-13C6 disodium

    UDP-D-Glucose-13C6 disodium

    		 Isotope-Labeled Compounds Endogenous Metabolite P2Y Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Uridine 5′-diphosphoglucose- 13C6 (UDP-D-Glucose- 13C6) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032) . Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue .
    Uridine 5′-diphosphoglucose-13C6 disodium
  • HY-156203
    MRS4608

    		P2Y Receptor Inflammation/Immunology
    MRS4608 (Compound 17) is a selective P2Y14 receptor antagonist with IC50 values of 20 (hP2Y14R) and 21.4 nM (mP2Y14R). MRS4608 has anti-inflammatory activity and can reduce the infiltration of eosinophils. MRS4608 can be used for the researches of inflammation and immunology, such as asthma .
    MRS4608
  • HY-172226
    P2Y14R antagonist 3

    		P2Y Receptor Inflammation/Immunology
    P2Y14R antagonist 3 (Compound A) is a potent and orally active P2Y14R antagonist with an IC50 value of 23.60 nM and a Kd value of 7.26 μM. P2Y14R antagonist 3 can reduce the degree of lung injury in the Lipopolysaccharides (LPS) (HY-D1056)-induced acute lung injury mice. P2Y14R antagonist 3 can be used for inflammatory diseases .
    P2Y14R antagonist 3
  • HY-N7032S
    Uridine 5′-diphosphoglucose-13C disodium

    UDP-D-Glucose-13C disodium

    		 Isotope-Labeled Compounds Endogenous Metabolite P2Y Receptor Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Uridine 5′-diphosphoglucose- 13C (UDP-D-Glucose- 13C) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032) . Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue .
    Uridine 5′-diphosphoglucose-13C disodium
  • HY-137607A
    UMP-CP trisodium

    		P2Y Receptor Inflammation/Immunology
    UMP-CP trisodium (Compound 3), a nucleotide, is a P2Y14 receptor agonist with an EC50 of 160  nM for P2Y14 receptor over the P2Y6 receptor. UDP trisodium can be used for pain, diabetes, cystic fibrosis and other pulmonary diseases research .
    UMP-CP trisodium
  • HY-168139
    MRS4865

    		P2Y Receptor Cancer
    MRS4865 (compund 7a) is a chimera of a P2Y14 receptor antagonist and a UDP-glucose agonist that protects against neuropathic pain .
    MRS4865
  • HY-124987
    MRS4458

    		Endogenous Metabolite Inflammation/Immunology
    MRS4458 is a P2Y14 receptor antagonist with anti-inflammatory activity. MRS4458 mediates inflammatory activity by activating the motility of neutrophils. The design of MRS4458 is based on the interaction with the P2Y14 receptor and optimized by molecular dynamic simulation. MRS4458 performs well in terms of shape and complementarity with the receptor. The prediction that the 5-phenyl group of MRS4458 is substituted with thiophene is generally consistent with empirical results. The biological activity of MRS4458 was verified by fluorescence assay, showing its potent antagonistic effect .
    MRS4458
  • HY-103055
    PPTN mesylate

    		P2Y Receptor Inflammation/Immunology
    PPTN mesylate is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN mesylate exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .
    PPTN mesylate
  • HY-173407
    P2Y14R antagonist 4

    		P2Y Receptor Interleukin Related Inflammation/Immunology
    P2Y14R antagonist 4 (Compound 25l) is an orally active P2Y14R antagonist (IC50: 5.6 nM) with superior binding affinity to P2Y14R over PPTN. P2Y14R antagonist 4 has anti-inflammatory activity and reduces LPS (HY-D1056)-induced proinflammatory cytokines (IL-1β, IL-6, and TNF-α) release .
    P2Y14R antagonist 4
  • HY-116295
    MRS2690

    		P2Y Receptor p38 MAPK Calcium Channel Cardiovascular Disease
    MRS2690 is a selective P2Y14 receptor agonist. MRS2690 inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 induces intracellular calcium mobilization, activates P38 and stimulates [ 35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690can be used for ischemic heart disease .
    MRS2690
  • HY-116295A
    MRS2690 disodium

    		P2Y Receptor p38 MAPK Calcium Channel Cardiovascular Disease
    MRS2690 disodium is a selective P2Y14 receptor agonist. MRS2690 disodium inhibits adenylyl cyclase activity, thereby reducing intracellular cAMP levels and mediating concentration-dependent vasoconstriction of porcine coronary arteries. MRS2690 disodium induces intracellular calcium mobilization, activates P38 and stimulates [ 35S]GTPγS binding to RBL-2H3 cell membranes. MRS2690 enhances antigen (NP-BSA)-, C3a-induced β-hexosaminidase (β-Hex) release. MRS2690 disodium can be used for ischemic heart disease .
    MRS2690 disodium
  • HY-156220
    MRS4654

    		P2Y Receptor Neurological Disease Inflammation/Immunology
    MRS4654 is an efficient and neutral P2Y14R (hP2Y14R IC50 = 15.0 nM, mP2Y14R IC50 = 18.6 nM) antagonist. MRS4654 has analgesic and anti-inflammatory effects. MRS4654 can be used for research on asthma and neuropathic pain .
    MRS4654
  • HY-N7114
    Chloramphenicol succinate

    		Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase Infection Inflammation/Immunology
    Chloramphenicol succinate is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate exerts a significant inhibitory effect on colitis. Chloramphenicol succinate can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
    Chloramphenicol succinate
  • HY-122211
    MRS2802

    		Endogenous Metabolite Cardiovascular Disease
    MRS2802 is a P2Y14 receptor agonist with an EC50 value of 63 nM. MRS2802 can effectively activate the P2Y14 receptor and may play a role in regulating platelet function. The selectivity and activity of MRS2802 are conducive to in-depth research on the biological functions and pharmacological properties of P2Y receptors. The development of MRS2802 provides a potential inhibitory strategy for the search for new antiplatelet compounds .
    MRS2802
  • HY-143890
    MRS4738

    		P2X Receptor Cardiovascular Disease Inflammation/Immunology
    MRS4738 is a potent and high affinity P2Y14R antagonist. MRS4738 exhibits anti-hyperallodynic and antiasthmatic activity in vivo .
    MRS4738
  • HY-RS09926
    P2ry14 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) P2Y Receptor Others

    P2ry14 Mouse Pre-designed siRNA Set A contains three designed siRNAs for P2ry14 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    P2ry14 Mouse Pre-designed siRNA Set A
    P2ry14 Mouse Pre-designed siRNA Set A
  • HY-RS09925
    P2RY14 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) P2Y Receptor Others

    P2RY14 Human Pre-designed siRNA Set A contains three designed siRNAs for P2RY14 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    P2RY14 Human Pre-designed siRNA Set A
    P2RY14 Human Pre-designed siRNA Set A
  • HY-131821
    5'-TMPS

    Thymidine-5'-O-monophosphorothioate

    		 P2Y Receptor Others
    5'-TMPS (Thymidine-5'-O-monophosphorothioate) is a selective partial agonist of P2Y6R and an antagonist of P2Y14R. Additionally, 5'-TMPS acts as a positive regulator of angiogenesis, exhibiting pro-angiogenic effects
    5'-TMPS
  • HY-110369
    MRS2905 trisodium

    a,β-Methylene-2-thio-UDP trisodium

    		 P2Y Receptor Inflammation/Immunology
    MRS2905 (α,β-Methylene-2-thio-UDP) trisodium is a selective P2Y14R agonist with an EC50 of 0.92 nM. MRS2905 trisodium is inactive at the UDP-activated P2Y6 receptor, and at other P2Y receptors .
    MRS2905 trisodium
  • HY-167855
    MRS4833

    		P2Y Receptor Inflammation/Immunology
    MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .
    MRS4833
  • HY-167855S
    1’-Epi Gemcitabine hydrochloride-13C,15N2

    		Isotope-Labeled Compounds P2Y Receptor Inflammation/Immunology
    1’-Epi Gemcitabine hydrochloride- 13C, 15N2 is the 13C- and 15N-labeled MRS4833 (HY-167855). MRS4833 (compound 15) is an orally active, potent, competitive P2Y14R antagonist with an of IC50 of 5.92 nM for hP2Y14R and an IC50 of 4.8 nM for mP2Y14R. MRS4833 reduces airway eosinophilia in a protease-mediated asthma model and reverses chronic neuropathic pain in a mouse CCI model .
    1’-Epi Gemcitabine hydrochloride-13C,15N2
  • HY-W010832R
    Uridine-5'-diphosphate disodium salt (Standard)

    		Reference Standards P2Y Receptor DNA/RNA Synthesis Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    Uridine-5'-diphosphate disodium salt is a potent, selective P2Y6 receptor native agonist (EC50=300 nM; pEC50=6.52 for human P2Y6 receptor). Uridine-5'-diphosphate disodium salt, an endogenous metabolite, catalyzes the glucuronidation of a wide array of substrates and is used in nucleic acid (RNA) biosynthesis .
    Uridine-5'-diphosphate disodium salt (Standard)
  • HY-N7114AR
    Chloramphenicol succinate sodium (Standard)

    		Reference Standards Bacterial Drug Intermediate P2Y Receptor Succinate Dehydrogenase Infection Inflammation/Immunology
    Chloramphenicol succinate sodium (Standard) is the analytical standard of Chloramphenicol succinate sodium. This product is intended for research and analytical applications. Chloramphenicol succinate sodium is a prodrug of Chloramphenicol (HY-B0239), acting as a P2Y14R inhibitor with an IC50 of 1.585 nM. Chloramphenicol succinate sodium serves as a competitive substrate and inhibitor of succinate dehydrogenase (SDH), which may account for its toxicity. Chloramphenicol succinate sodium exerts a significant inhibitory effect on colitis. Chloramphenicol succinate sodium can be used in research related to myelosuppression, gray baby syndrome, aplastic anemia, bacterial meningitis and inflammatory bowel disease .
    Chloramphenicol succinate sodium (Standard)
  • HY-107752A
    GPR17 agonist 1

    		Orphan GPCR P2Y Receptor Neurological Disease
    GPR17 agonist 1 is a selective and potent GPR17 agonist with an EC50 of 35 pM. GPR17 agonist 1 also shows weak activation of P2Y Receptor. GPR17 agonist 1 can be used for the research of neurological disease .
    GPR17 agonist 1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: